That clinic sounds awesome. I'm curious - when you were in the Tovaxin trial and even now, do you see your neurologist every time you go in?
patientx wrote:I haven't been at this very long, but I haven't received near that level of attention. I'm starting to think a move to Lexington may not be a bad idea, just to go to that clinic.
patientx wrote:You know, I briefly thought about whether it might be a good idea to move, to be near a good MS center (with the right clinical studies). The problem I have is that all my family lives near where I am now.
JanethePain wrote:patientx wrote:I haven't been at this very long, but I haven't received near that level of attention. I'm starting to think a move to Lexington may not be a bad idea, just to go to that clinic.
IF we get to re-start The Big T, I'm going to see if I can switch there. My mom lives all of five minutes away from the site. If I hadn't been so doggoned impatient, I probably would have been there... but I didn't think Kentucky would offer a trial site. So I jumped on the first "take" I got--although I ended up loving the Columbus gang, it WAS pain in the keester having to make such a trip each and every time!
av8rgirl wrote:I had an appt with my neurologist today and we went over the MRI I had a couple of weeks ago. This one was compared to the one that was done prior to my entry into the clinical trial. I have many new lesions.
So not only did I not get a departure debrief but when asked for information about the brain MRIs, the clinical trial neurologist told my neurologist there had been no change in my MRIs. I do believe that was misinformation.
I will most likely be going back on Betaseron soon.
I am very unhappy with the clinical trial doc who conducted the site where I was enrolled. I am not sure what to do about all of this. I certainly hope that Opexa is reading this because they should be....
An analysis of the MS Quality of Life Inventory Data (MSQLI) from the 150 patient study has shown that in the complete modified intent to treat (mITT) population (n=142), patients treated with Tovaxin demonstrated a statistically significant improvement in the Impact of Visual Impairment Scale scores (p=0.028) compared to those on placebo. This improvement was observed within six months of completing the full course of treatment.
An abstract highlighting key clinical, magnetic resonance imaging (MRI), epitope and Quality of Life data from the landmark TERMS study has been accepted as a poster presentation at the 61st Annual Meeting of the American Academy of Neurology (AAN) in April 2009. The presentation will be given by Edward Fox, MD, PhD, director of the Multiple Sclerosis Clinic of Central Texas and the study’s principal investigator and co-author of the TERMS study.
Users browsing this forum: No registered users